The FY25-29 Strategic Plan enables the National Psoriasis Foundation to address the hurdles faced in today's health care landscape, as we accelerate our drive to find a cure. The strategic plan is built around two goals of equal importance: 

Goal 1: Cure Psoriatic Disease

NPF is steadfast in our commitment to cure psoriatic disease. To realize this, we will invest in passing the milestones necessary to reach a world free from psoriatic disease and its burdens. We will also support the expansion of the psoriatic disease research infrastructure and grow the clinical workforce across disciplines.

Goal 2: Optimize Health for Everyone Living with Psoriatic Disease, Now

NPF is working to ensure access to life-changing therapies. We have begun bridging better connections between people with psoriatic disease and qualified health care providers, while continuing to pay special attention to traditionally underserved populations.

Moving Forward Together

NPF developed its strategic plan with input from all stakeholders in the psoriatic disease and health advocacy communities. Key contributions were made by expert dermatologists, rheumatologists, and researchers, in addition to medical professionals, advocacy organizations and community groups, and industry partners.

Most importantly, the plan is informed by those who live with psoriatic disease, including individuals from traditionally underserved populations. This approach was used to put people with the disease – and those who know how best to treat it – at the forefront of the decision-making process as the plan evolved.

Thank you for your continued partnership as we improve access to care and continue provide exemplary support to the 8 million people in the U.S. and 125 million worldwide who are living with psoriatic disease. 

Successes in Recent Years

Because of you, NPF:

• Launched and funded the PsA Diagnostic Test Grant and Psoriasis Prevention Initiative, leading to groundbreaking advancements. 
• Included psoriatic disease in the Accelerating Medicines Partnership for immune-mediated diseases, unlocking new collaborative research opportunities and funding. 
• Helped 36 states pass step therapy or copay accumulator legislation, creating better access to prescribed care. 
• Advocated, a Medicare out-of-pocket cap and smoothing mechanism goes into effect in 2025. 
• Updated the guidelines for the treatment of psoriatic disease alongside the American Academy of Dermatology and the American College of Rheumatology. 
• Delivered the latest information and resources to over 4 million visitors per year at psoriasis.org.